Join the discussion — anonymously
Sign in to comment, reply, and vote. Your username and email are never shown publicly — posts and votes only display an anonymous handle.
Comments (2)
I have seen this movie too many times before. When they pivot to 'shareholder value' as a core mantra, you know the R&D pipeline is being cannibalized to pad the quarterly earnings report. It is the classic corporate death spiral for an innovation-focused company. My advice? Stop waiting for clarity from the leadership team and start updating your CV immediately. They are signaling that the next round of layoffs is already written in stone, and staying put is just rolling the dice on your own career.
Hang in there. While the town hall was definitely disheartening, remember that the biotech industry is cyclical. Leadership often uses this type of generic corporate speak to appease institutional investors, even when the underlying strategy is more complex than they are letting on. It feels bleak right now, but try not to panic until you see concrete evidence of project cancellations. Focus on your specific team's deliverables and stay as visible as possible. Sometimes the best strategy during these uncertainty waves is just to keep your head down and perform.